支气管扩张症，慢性阻塞性肺病等疾病的诊治及基础研究；
Diagnosis, treatment, and basic research of bronchiectasis, chronic obstructive pulmonary disease (COPD), and other related diseases.
本人在过去三年中发表数篇具有学术影响力的论文，累计影响因子近40分。2022年在《Thorax》上以独立一作的身份发表研究论文。临床工作中主攻研究支气管扩张症与自身免疫系统疾病的关系，通过分析UK biobank GWAS数据，得出支气管扩张症与克罗恩病、类风湿性关节炎和溃疡性结肠炎之间存在显著的遗传相关性。同年本人利用药物靶向孟德尔随机化的研究方法，使用人类基因组内的遗传变异作为工具变量，通过随机分配来评估药物对特定靶点或生物标志物的影响，发现抗糖尿病相关药物可改善COPD患者的肺功能。在工作期间，本人参与多项国内国际学术会议，即将在奥地利维也纳举办的2024年欧洲呼吸年会做壁报演讲以及在中国香港举办的2024亚太呼吸年会进行口头报告演讲。
I have published several academically influential papers in the past three years, with a cumulative impact factor of nearly 40. In 2022, I published a research paper as the first author in "Thorax". In August 2022, after working in the Department of Respiratory and Critical Care Medicine at the Shanghai Pulmonary Hospital, my clinical focus shifted to studying the relationship between bronchiectasis and autoimmune diseases. By analyzing UK Biobank GWAS data, I found a significant genetic correlation between bronchiectasis and Crohn’s disease, rheumatoid arthritis, and ulcerative colitis. In the same year, I utilized drug targeting Mendelian randomization research methods, using genetic variations within the human genome as instrumental variables, to assess the impact of drugs on specific targets or biomarkers through random allocation. I discovered that anti-diabetic drugs can improve lung function in COPD patients. During this period, I participated in several domestic and international academic conferences. I am scheduled to present a poster at the 2024 European Respiratory Society Annual Congress in Vienna, Austria, and give an oral presentation at the 2024 Asia-Pacific Respiratory Society Annual Congress in Hong Kong, China.
